CL2021000731A1 - Derivados de indano para uso en el tratamiento de infección bacteriana - Google Patents

Derivados de indano para uso en el tratamiento de infección bacteriana

Info

Publication number
CL2021000731A1
CL2021000731A1 CL2021000731A CL2021000731A CL2021000731A1 CL 2021000731 A1 CL2021000731 A1 CL 2021000731A1 CL 2021000731 A CL2021000731 A CL 2021000731A CL 2021000731 A CL2021000731 A CL 2021000731A CL 2021000731 A1 CL2021000731 A1 CL 2021000731A1
Authority
CL
Chile
Prior art keywords
treatment
bacterial infection
indane derivatives
indane
antibiotics
Prior art date
Application number
CL2021000731A
Other languages
English (en)
Inventor
Simon Leiris
David Thomas Davies
Martin Everett
Nicolas Sprynski
Lilha Beyria
Thomas David Pallin
Andrew Peter Cridland
Toby Jonathan Blench
Richard Leonard Elliott
David Edward Clark
Original Assignee
Antabio Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP18290106.6A external-priority patent/EP3628666A1/en
Application filed by Antabio Sas filed Critical Antabio Sas
Publication of CL2021000731A1 publication Critical patent/CL2021000731A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención se refiere a un compuesto que es un indano de acuerdo con la fórmula (I), o una sal farmacéuticamente aceptable del mismo, en donde R1, R2, R3, R4, R5, R6, n y p son como se definen en la presente. Los compuestos son útiles en el tratamiento de infección antibacteriana ya sea como antibióticos independientes o en combinación con antibióticos adicionales.
CL2021000731A 2018-09-25 2021-03-24 Derivados de indano para uso en el tratamiento de infección bacteriana CL2021000731A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18290106.6A EP3628666A1 (en) 2018-09-25 2018-09-25 Indane derivatives for use in the treatment of bacterial infection
EP18290104 2018-09-26
EP18197365 2018-09-27

Publications (1)

Publication Number Publication Date
CL2021000731A1 true CL2021000731A1 (es) 2021-11-05

Family

ID=67439236

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2021000731A CL2021000731A1 (es) 2018-09-25 2021-03-24 Derivados de indano para uso en el tratamiento de infección bacteriana
CL2021000729A CL2021000729A1 (es) 2018-09-25 2021-03-24 Derivados de indano para el uso en el tratamiento de infección bacteriana

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2021000729A CL2021000729A1 (es) 2018-09-25 2021-03-24 Derivados de indano para el uso en el tratamiento de infección bacteriana

Country Status (14)

Country Link
US (2) US12247013B2 (es)
EP (2) EP3856729A1 (es)
JP (2) JP7429993B2 (es)
KR (2) KR102833669B1 (es)
CN (2) CN113166085B (es)
AU (2) AU2019349438B2 (es)
BR (2) BR112021005651A2 (es)
CA (2) CA3113697A1 (es)
CL (2) CL2021000731A1 (es)
IL (2) IL281770B2 (es)
MA (2) MA53706A (es)
MX (2) MX2021003485A (es)
SG (2) SG11202102791SA (es)
WO (2) WO2020064174A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113166085B (zh) * 2018-09-25 2024-04-09 安塔比奥公司 用于治疗细菌感染的茚满衍生物
US20240016941A1 (en) * 2020-03-24 2024-01-18 Antabio Sas Combination therapy

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ206920A (en) 1983-01-28 1986-10-08 Schering Corp Phosphorus-containing amide,urea or carbamate derivatives and pharmaceutical compositions
US5457196A (en) * 1991-09-27 1995-10-10 Merrell Dow Pharmaceuticals Inc. 2-substituted indane-2-carboxyalkyl derivatives useful as inhibitors of enkephalinase and ACE
JP3126541B2 (ja) 1993-03-26 2001-01-22 千寿製薬株式会社 ベンゾチアゾール誘導体、その製法及びその用途
JPH0782259A (ja) * 1993-09-14 1995-03-28 Senju Pharmaceut Co Ltd スクシンアミド酸誘導体及びそれを含有する糖尿病合併症治療剤
DE4339198A1 (de) 1993-11-16 1995-05-18 Max Planck Gesellschaft Verwendung bestimmter aromatischer Derivate als Fungizide und/oder Antibiotika
US6514996B2 (en) 1995-05-19 2003-02-04 Kyowa Hakko Kogyo Co., Ltd. Derivatives of benzofuran or benzodioxole
CA2261662A1 (en) 1996-07-23 1998-01-29 Daiichi Pharmaceutical Co., Ltd. Sorbefacients
JPH11130761A (ja) 1997-10-24 1999-05-18 Otsuka Pharmaceut Co Ltd ベンゾチアゾール誘導体
AR036237A1 (es) 2001-07-27 2004-08-25 Bayer Corp Derivados del acido indan acetico, intermediarios, y metodo para su preparacion, composicion farmaceutica y el uso de dichos derivados para la manufactura de un medicamento
UA79755C2 (en) 2002-04-16 2007-07-25 Bayer Pharmaceuticals Corp Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
US20050187249A1 (en) 2002-05-13 2005-08-25 Daiichi Pharmaceutical Co., Ltd. Lypohilization product
PA8597401A1 (es) 2003-03-14 2005-05-24 Pfizer Derivados del acido 3-(1-[3-(1,3-benzotiazol-6-il) propilcarbamoil] cicloalquil) propanoico como inhibidores de nep
US20050070543A1 (en) 2003-07-11 2005-03-31 Pharmacia Corporation Compositions of a chromene or phenyl acetic acid cyclooxygenase-2 selective inhibitor and an ACE inhibitor for the treatment of central nervous system damage
AU2005282466B2 (en) 2004-09-08 2011-03-10 Merck Sharp & Dohme Corp. Monocyclic anilide spirolactam CGRP receptor antagonists
FR2883876B1 (fr) 2005-03-30 2007-05-04 Servier Lab Derives d'indanyl-piperazines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN102516192A (zh) 2005-05-11 2012-06-27 雅培制药有限公司 香草素受体亚型1(vr1)拮抗剂及其用途
EP1891059B1 (de) 2005-05-25 2012-12-05 Merck Patent GmbH Pyran-dioxan-derivate und deren verwendung in flüssigkristallinen medien
WO2007031860A1 (en) 2005-09-15 2007-03-22 Pfizer Japan Inc. Indane substituted benzimidazoles and their use as acid pump inhibitors
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
WO2007099423A1 (en) 2006-03-02 2007-09-07 Pfizer Products Inc. 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists
WO2008036967A2 (en) 2006-09-22 2008-03-27 Reddy Us Therapeutics, Inc. Novel heterocyclic compounds as lasy activators
MX2009011615A (es) 2007-06-05 2009-11-10 Sanofi Aventis Acidos benzoilamino-indan-2-carboxilicos sustituidos y compuestos relacionados.
EP2141164A1 (en) 2008-07-01 2010-01-06 Mutabilis New 1,2,4-triazine derivatives and biological applications thereof
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
WO2012116415A1 (en) 2011-03-02 2012-09-07 Bionomics Limited Novel small-molecules as therapeutics
JP6367214B2 (ja) 2012-11-30 2018-08-01 バイエル・クロップサイエンス・アクチェンゲゼルシャフト 二成分殺菌剤混合物又は二成分殺害虫剤混合物
GB201310542D0 (en) 2013-06-13 2013-07-31 Antabio Sas Compounds
GB201704476D0 (en) * 2017-03-21 2017-05-03 Antabio Sas Chemical compounds
JP7418395B2 (ja) 2018-03-21 2024-01-19 リレー セラピューティクス， インコーポレイテッド Ｓｈｐ２ホスファターゼ阻害剤およびこれらの使用方法
CN113166085B (zh) 2018-09-25 2024-04-09 安塔比奥公司 用于治疗细菌感染的茚满衍生物
SG11202102105VA (en) 2018-09-26 2021-04-29 Alkahest Inc Methods and compositions for treating aging-associated impairments using ccr3-inhibitors

Also Published As

Publication number Publication date
AU2019349438A1 (en) 2021-04-15
KR20210087448A (ko) 2021-07-12
CN113166085B (zh) 2024-04-09
WO2020064174A1 (en) 2020-04-02
BR112021005651A2 (pt) 2021-06-22
JP7429993B2 (ja) 2024-02-09
MA53707A (fr) 2021-12-29
SG11202102790PA (en) 2021-04-29
AU2019351551B2 (en) 2024-12-12
IL281770A (en) 2021-05-31
MX2021003485A (es) 2021-09-10
SG11202102791SA (en) 2021-04-29
US12286411B2 (en) 2025-04-29
CL2021000729A1 (es) 2021-11-05
JP2022502486A (ja) 2022-01-11
CN113166084B (zh) 2024-06-04
BR112021005532A2 (pt) 2021-06-29
IL281770B2 (en) 2025-03-01
CA3113689A1 (en) 2020-04-02
AU2019349438B2 (en) 2024-12-12
EP3856730A1 (en) 2021-08-04
MA53706A (fr) 2021-12-29
KR20210087025A (ko) 2021-07-09
CN113166085A (zh) 2021-07-23
IL281770B1 (en) 2024-11-01
JP2022502485A (ja) 2022-01-11
CN113166084A (zh) 2021-07-23
JP7429992B2 (ja) 2024-02-09
US12247013B2 (en) 2025-03-11
KR102833669B1 (ko) 2025-07-11
US20220112169A1 (en) 2022-04-14
WO2020064173A1 (en) 2020-04-02
IL281780A (en) 2021-05-31
EP3856729A1 (en) 2021-08-04
CA3113697A1 (en) 2020-04-02
US20210347748A1 (en) 2021-11-11
MX2021003498A (es) 2021-09-10
AU2019351551A1 (en) 2021-04-15
KR102833646B1 (ko) 2025-07-11

Similar Documents

Publication Publication Date Title
MX2018005382A (es) Compuestos de biaril-monobactam y metodos de uso de los mismos para el tratamiento de infecciones bacterianas.
CO2022008091A2 (es) Inhibidores de kras g12c
CO2020012824A2 (es) Compuestos de 4-aminoisoindolina-1,3-diona sustituidos y su uso para el tratamiento de linfoma
ECSP18005828A (es) Inhibidores de metalo-beta-lactamasa
MX2022012313A (es) Oxisteroles y metodos de uso de los mismos.
CO2019005534A2 (es) Compuestos de heterociclo tetracíclicos útiles como inhibidores de la integrasa del vih
CL2021001190A1 (es) Compuestos de azalactam como inhibidores de hpk1
MX379474B (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales
MX2020002825A (es) Beta-hidroxietilaminas heteroaril sustituidas para su uso en el tratamiento de hiperglucemia.
CL2020001147A1 (es) Compuestos antibacterianos
CL2020002139A1 (es) Compuestos de sulfonimidoilpurinona 7-sustituidos y sus derivados para el tratamiento y prevención del cáncer de hígado.
MX2019013291A (es) Compuestos y metodos para tratar infecciones bacterianas.
CL2021000731A1 (es) Derivados de indano para uso en el tratamiento de infección bacteriana
MX2018001022A (es) Antibiotico aminoglucosido novedoso efectivo contra bacterias resistentes a multiples farmacos.
CL2020003380A1 (es) Compuestos que aumentan la actividad del proteosoma.
MX2023011715A (es) Compuestos de oxoisoindolina sustituidos con piridinilo.
CO2020016080A2 (es) Compuestos
BR112017015744A2 (pt) composto apresentando uma estrutura de fórmula (i), um sal farmaceuticamente aceitável do mesmo ou um isômero ótico do mesmo, composição farmacêutica e uso do composto de fórmula (i) para o tratamento e prevenção de mycobacterium tuberculosis ou outras infecções microbianas
ECSP23080267A (es) Compuestos de lactivicina, su preparación y uso como agentes antibacterianos
CL2017001276A1 (es) Derivados de benzotiazol antibacterianos
ECSP24038829A (es) Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno
MX2017015988A (es) Derivados de manosa para tratar infecciones bacterianas.
BR112019002195A2 (pt) inibidores de beta-lactamase
MX2021005234A (es) Compuestos para el tratamiento de la infeccion por arenavirus.
CL2021003592A1 (es) Compuestos y métodos de uso de los mismos como agentes antibacterianos.